Cargando…
Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection
INTRODUCTION: Direct-acting antivirals (DAAs) represent a breakthrough in hepatitis C virus (HCV) treatment as they directly inhibit HCV nonstructural (NS) proteins (NS3/4A, NS5A, and NS5B). However, ongoing debates exist regarding their relationship with hepatocellular carcinoma (HCC) whose inciden...
Autores principales: | Zidan, Ahmad M., Saad, Eman A., Ibrahim, Nasser E., Hashem, Medhat H., Mahmoud, Amal, Hemeida, Alaa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113831/ https://www.ncbi.nlm.nih.gov/pubmed/34013078 http://dx.doi.org/10.1016/j.heliyon.2021.e06908 |
Ejemplares similares
-
PHARMIP: An insilico method to predict genetics that underpin adverse drug reactions
por: Zidan, Ahmad M., et al.
Publicado: (2019) -
In silico identification of potential key regulatory factors in smoking-induced lung cancer
por: El-aarag, Salem A., et al.
Publicado: (2017) -
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014) -
Influenza Antiviral Subversion: Now the Host Is in on the Act
por: Yepsen, Erin N., et al.
Publicado: (2021) -
Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics
por: Tavis, John E, et al.
Publicado: (2011)